11 recruiting, 5 completed, 2 not yet recruiting, 1 terminated. 6 Phase 1, 6 Phase 2, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Recruiting 3 |
| Phase 2 | 6 | Recruiting 4, Completed 1, Not yet recruiting 1 |
| Not applicable | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Primary Central Nervous System Lymphoma (PCNSL): new trials by email Literature Review of Primary Central Nervous System Lymphoma (PCNSL) trials Research Report on Primary Central Nervous System Lymphoma (PCNSL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Registry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China High-dose methotrexate-based therapy, Bruton tyrosine kinase inhibitor-based therapy - Primary Central Nervous System Lymphoma (PCNSL) | Recruiting | Xiaohui Ren | 400 | 2026-10-01 | 2026-09-30 | |
| Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL Zanubrutinib, Lenalidomide - Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib | Phase 2 | Recruiting | Xiaohui Ren | 33 | 2026-09-25 | 2026-09-28 |
| Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma Pomalidomide, PD-1 / PD-L1 monoclonal antibody, XPO1 inhibitor - Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Beijing Tongren Hospital | 43 | 2026-04-01 | 2026-04-15 |
| PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. PD -1/PD-L1 monoclonal antibody, Rituximab (R), Methotrexate - Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 50 | 2026-02-07 | 2026-02-13 |
| Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma Relmacabtagene autoleucel and transplantation - Primary Central Nervous System Lymphoma (PCNSL) | Not applicable | Not yet recruiting | Zhengzhou University | 30 | 2025-10-07 | 2025-09-30 |
| A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants Tirabrutinib - Primary Central Nervous System Lymphoma (PCNSL) | Phase 1 | Completed | Ono Pharmaceutical Co., Ltd. | 40 | 2025-10-01 | 2026-06-26 |
| A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) ibrutinib, Epcoritamab - Primary Central Nervous System Lymphoma (PCNSL), Primary Central Nervous System Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2025-08-13 | 2026-07-14 |
| Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B-Cell Lymphoma | Recruiting | Ting YANG | 20 | 2025-03-01 | 2025-11-18 | |
| Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Nationwide Study Primary Central Nervous System Lymphoma (PCNSL) | Completed | Ono Pharmaceutical Co., Ltd. | 24 | 2025-02-03 | 2026-05-20 | |
| Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL Induction therapy-2 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor), Consolidation therapy with ASCT after TB (Thiotepa plus Busulfan) preconditioning, Consolidation therapy-4 cycles of VPX (Teniposide, PD-1 monoclonal antibody plus Selinixor) - Primary Central Nervous System Lymphoma (PCNSL) | Not applicable | Recruiting | The First Affiliated Hospital of Soochow University | 40 | 2025-01-02 | 2025-07-20 |
| High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) Zanubrutinib , Thiotepa, Methotrexate , Thiotepa and Zanubrutinib, ASCT±Zanubrutinib - Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 30 | 2025-01-01 | 2024-10-17 |
| Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation - Primary Central Nervous System Lymphoma (PCNSL), CNS Lymphoma Treatment | Not applicable | Recruiting | FengYan Jin | 41 | 2022-12-02 | 2025-04-27 |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NX-5948 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Recruiting | Nurix Therapeutics, Inc. | 572 | 2022-04-13 | 2026-07-02 |
| High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma High dose Gemcitabine, Busulfan, and Thiotepa as conditioning therapy - Primary Central Nervous System Lymphoma (PCNSL) | Phase 2 | Recruiting | Sichuan University | 34 | 2022-01-01 | 2025-06-11 |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NX-2127 - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 1 | Recruiting | Nurix Therapeutics, Inc. | 248 | 2021-05-05 | 2026-03-20 |
| Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. Rituximab - Primary Central Nervous System Lymphoma (PCNSL) | Phase 1 | Completed | National Health Research Institutes, Taiwan | 22 | 2021-02-22 | 2026-09-17 |
| Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy Nivolumab - Primary Central Nervous System Lymphoma (PCNSL) | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 14 | 2020-05-22 | 2026-01-27 |
| Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL) Tumor samples and MRI - Primary Central Nervous System Lymphoma (PCNSL) | Unknown | Assistance Publique - Hôpitaux de Paris | 100 | 2020-05-12 | 2022-02-18 | |
| Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) Ibrutinib, Lenalidomide, Rituximab - Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 25 | 2019-01-22 | 2026-01-29 |
| Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors Primary Central Nervous System Lymphoma (PCNSL) | Terminated | OHSU Knight Cancer Institute | 80 | 2008-07-01 | 2017-04-21 |
Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Waldenstrom Macroglobulinemia (2) · Brain Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Neurotoxicity Syndromes (1) · Rare Diseases (1) · Recurrence (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Disease Attributes (4) · Lymphoma, B-Cell (4) · Lymphoma, Non-Hodgkin (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Lymphoma (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2)
Rituximab (4) · Thiotepa (4) · Methotrexate (3) · Busulfan (2) · Lenalidomide (2) · ibrutinib (2) · zanubrutinib (2) · Behavior Therapy (1) · Cytarabine (1) · Gemcitabine (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Teniposide (1) · Transplantation (1) · acalabrutinib (1)
Memorial Sloan Kettering Cancer Center (3) · Nurix Therapeutics, Inc. (2) · Ono Pharmaceutical Co., Ltd. (2) · Xiaohui Ren (2) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Tongren Hospital (1) · FengYan Jin (1) · National Health Research Institutes, Taiwan (1) · OHSU Knight Cancer Institute (1) · Sichuan University (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Soochow University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Ting YANG (1) · Zhengzhou University (1)
China (9) · United States (7) · France (2) · Taiwan (2) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Christian Grommes, MD (3) · Edward A Neuwelt, MD (1) · Kwang-Yu Chang, M.D (1) · Liang Wang, M.D. (1) · Ming Chung Wang, M.D (1) · Project Leader (1) · Shang-Ju Wu, M.D (1) · Su-Peng Yeh, M.D (1)
PMID 36375120, PMID 34132444, PMID 35834762, PMID 40269592
2014 (1), 2023 (1), R01NS033618 (1)